blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3912637

EP3912637 - IL-15-BASED MOLECULES AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  06.03.2026
Database last updated on 09.04.2026
FormerRequest for examination was made
Status updated on  22.10.2021
Most recent event   Tooltip02.04.2026New entry: Renewal fee paid 
Applicant(s)For all designated states
Altor BioScience, LLC
9920 Jefferson Blvd
Culver City, CA 90232 / US
[2026/10]
Former [2021/47]For all designated states
Altor BioScience Corporation
2810 North Commerce Parkway
Miramar, Florida 33025 / US
Inventor(s)01 / LIU, Bai
Cooper City, FL 33024 / US
02 / RHODE, Peter
Miami, FL 33185 / US
03 / XU, Wenxin
Pembroke Pines, FL 33025 / US
04 / WONG, Hing C.
Weston, FL 33332 / US
 [2021/47]
Representative(s)AWA Sweden AB
Box 45086
104 30 Stockholm / SE
[N/P]
Former [2021/47]AWA Sweden AB
P.O. Box 45086
104 30 Stockholm / SE
Application number, filing date21173707.730.06.2015
[2021/47]
Priority number, dateUS201462018899P30.06.2014         Original published format: US 201462018899 P
[2021/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3912637
Date:24.11.2021
Language:EN
[2021/47]
Search report(s)(Supplementary) European search report - dispatched on:EP22.10.2021
ClassificationIPC:A61K39/00, A61K39/385, A61P35/00
[2021/47]
CPC:
A61K38/2086 (EP,KR,US); A61K38/1793 (KR,US); A61K39/39558 (EP,KR,US);
A61K47/6425 (US); A61P31/18 (EP); A61P35/00 (EP,KR,US);
A61P35/02 (EP); A61P43/00 (EP); C07K14/5443 (EP,KR,US);
C07K14/7155 (EP,KR,US); C07K16/2818 (EP,KR,US); C07K16/2827 (EP,US);
C07K16/2887 (EP,US); C07K16/32 (EP); A61K2039/505 (KR);
A61K2300/00 (KR); A61K39/04 (US); C07K14/35 (US);
C07K16/2896 (US); C07K2317/732 (EP,KR,US); C07K2319/30 (EP,KR,US);
C07K2319/32 (US) (-)
C-Set:
A61K38/2086, A61K2300/00 (EP);
A61K39/39558, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/47]
TitleGerman:IL-15-BASIERTE MOLEKÜLE UND VERFAHREN ZUR VERWENDUNG DAVON[2021/47]
English:IL-15-BASED MOLECULES AND METHODS OF USE THEREOF[2021/47]
French:MOLÉCULES BASÉES SUR IL-15 ET LEURS PROCÉDÉS D'UTILISATION[2021/47]
Examination procedure12.05.2021Examination requested  [2021/47]
19.05.2022Amendment by applicant (claims and/or description)
10.03.2026Despatch of a communication from the examining division (Time limit: M04)
Parent application(s)   TooltipEP15815782.6  / EP3160498
Fees paidRenewal fee
12.05.2021Renewal fee patent year 03
12.05.2021Renewal fee patent year 04
12.05.2021Renewal fee patent year 05
12.05.2021Renewal fee patent year 06
12.05.2021Renewal fee patent year 07
27.06.2022Renewal fee patent year 08
31.03.2023Renewal fee patent year 09
25.06.2024Renewal fee patent year 10
27.06.2025Renewal fee patent year 11
31.03.2026Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[YA] WO2012175222  (CYTUNE et al.)
 [A] US2014134128  (WONG HING C et al.)
 [A] WO2014066527  (ADMUNE THERAPEUTICS LLC et al.)
 [YA]   MARIE VINCENT ET AL: "CS14-6. Development of two IL15 immunocytokines targeting either GD2- or CD20- tumoral bearing cells", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 56, no. 1, 1 October 2011 (2011-10-01), pages 102, XP002664482, ISSN: 1043-4666, [retrieved on 20110908], DOI: 10.1016/J.CYTO.2011.07.396

DOI:   http://dx.doi.org/10.1016/j.cyto.2011.07.396
 [YA]   MARIE VINCENT ET AL: "Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency", INTERNATIONAL JOURNAL OF CANCER, vol. 133, no. 3, 1 August 2013 (2013-08-01), pages 757 - 765, XP055151554, ISSN: 0020-7136, DOI: 10.1002/ijc.28059

DOI:   http://dx.doi.org/10.1002/ijc.28059
 [A]   W. XU ET AL: "Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma", CANCER RESEARCH, vol. 73, no. 10, 3 May 2013 (2013-05-03), pages 3075 - 3086, XP055151674, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-2357

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-2357
 [A]   P. YU ET AL: "Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model", CLINICAL CANCER RESEARCH, vol. 16, no. 24, 5 October 2010 (2010-10-05), pages 6019 - 6028, XP055123618, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-1966

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-10-1966
 [A]   MORTIER ERWAN ET AL: "Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 281, no. 3, 20 January 2006 (2006-01-20), pages 1612 - 1619, XP002394330, ISSN: 0021-9258, DOI: 10.1074/JBC.M508624200

DOI:   http://dx.doi.org/10.1074/jbc.M508624200
by applicantUS1975
 US8507
 US222
 US15198008
 US201113238925
 US5116964
 US5541087
 WO9734631
 WO9632478
 WO9429350
 WO9404689
 WO2005046449
 US5620939
 US201313769179
   OLEKSIEWICZ ET AL., ARCH BIOCHEM BIOPHYS, vol. 526, 2012, pages 124 - 31
   CHAN ET AL., NAT REV IMMUNOL, vol. 10, 2010, pages 301 - 16
   SLIWKOWSKI MXMELLMAN I, SCIENCE, vol. 341, 2013, pages 1192
   GERBER ET AL., MABS, vol. 1, 2009, pages 247 - 253
   NOVELLINO ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 54, 2005, pages 187 - 207
   FRANKE ET AL., CANCER BIOTHER RADIOPHARM, vol. 15, 2000, pages 459 - 76
   GUO ET AL., ADV CANCER RES, vol. 119, 2013, pages 421 - 475
   PARMIANI ET AL., J IMMUNOL, vol. 178, 2007, pages 1975 - 9
   PARDOLL DM, NATURE REV CANCER, vol. 12, 2012, pages 252 - 264
   THAVENTHIRAN T ET AL., J CLIN CELL IMMUNOL, vol. S12, 2012, pages 004
   GOLAY ET AL., BLOOD, vol. 122, 2013, pages 3482 - 91
   RICHARDS ET AL., MOL CANCER THER, vol. 7, 2008, pages 2517 - 27
   SINGLETON ET AL., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 1994
   "The Glossary of Genetics", 1988, SPRINGER VERLAG, article "The Cambridge Dictionary of Science and Technology"
   HALEMARHAM, THE HARPER COLLINS DICTIONARY OF BIOLOGY, 1991
   WAHL, G. M.S. L. BERGER, METHODS ENZYMOL, vol. 152, 1987, pages 507
   BENTONDAVIS, SCIENCE, vol. 196, 1977, pages 180
   GRUNSTEINHOGNESS, PROC. NATL. ACAD. SCI., USA, vol. 72, pages 3961
   LAWRENCIA ET AL., GENE THER, vol. 8, 2001, pages 760 - 8
   FRESHNEY, ANIMAL CELL CULTURE, 1987
   ZHU ET AL., J IMMUNOL, vol. 183, 2009, pages 3598 - 3607
   HAN ET AL., CYTOKINE, vol. 56, 2011, pages 804 - 810
   XU ET AL., CANCER RES, vol. 73, 2013, pages 3075 - 86
   WONG ET AL., ONCOLMMUNOLOGY, vol. 2, 2013, pages e26442
   CAPON ET AL., NATURE, vol. 337, 1989, pages 525 - 531
   CHAMOW ET AL., TRENDS BIOTECHNOL., vol. 14, 1996, pages 52 - 60
   ELLISON ET AL., NUCLEIC ACIDS RES, vol. 10, 1982, pages 4071 - 9
   REMINGTON: "The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
   "Encyclopedia of Pharmaceutical Technology", 1988, MARCEL DEKKER
   NOGAWA ET AL., J CLIN INVEST, vol. 115, 2005, pages 978 - 85
   NG ET AL., METHODS ENZYMOL, vol. 391, 2005, pages 304 - 13
   TYAGI ET AL., J UROL, vol. 171, 2004, pages 483 - 9
   TREVISANI ET AL., J PHARMACOL EXP THER, vol. 309, 2004, pages 1167 - 73
   TREVISANI ET AL., NAT NEUROSCI, vol. 5, 2002, pages 546 - 51
   AUSUBEL ET AL.: "Current Protocol in Molecular Biology", 1997, JOHN WILEY AND SONS
   THOMSON TM ET AL., J INVEST DERMATOL, vol. 85, 1985, pages 169 - 74
   URLAUBCHASM, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
   WALDMANN, T A, NATURE REV. IMMUNOL., vol. 6, 2006, pages 595 - 601
   MOSKAUG ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 15709
   PASTAN, I ET AL., CELL, vol. 47, 1986, pages 641
   PASTAN ET AL.: "Recombinant Toxins as Novel Therapeutic Agents", ANN. REV. BIOCHEM., vol. 61, 1992, pages 331, XP000431273, DOI: 10.1146/annurev.bi.61.070192.001555

DOI:   http://dx.doi.org/10.1146/annurev.bi.61.070192.001555
   "Chimeric Toxins'' Olsnes and Phil", PHARMAC. THER., vol. 25, 1982, pages 355
   GAIT, OLIGONUCLEOTIDE SYNTHESIS, 1984
   MEANS, G. E.FEENEY, R. E.: "Chemical Modification of Proteins", 1974, HOLDEN-DAY
   COLIGAN, CURRENT PROTOCOLS IN IMMUNOLOGY, 1991
   GRAHAM ET AL., J GEN. VIROL., vol. 36, 1977, pages 59
   GALFREMILSTEIN, METH. ENZYMOL., vol. 73, no. B, 1981, pages 3
   FLEER, R., CURRENT OPINION IN BIOTECHNOLOGY, vol. 3, no. 5, 1992, pages 486496
   SAMBROOK, MOLECULAR CLONING: A LABORATORY MANUAL, 1989
   WEIR: "Handbook of Experimental Immunology", 1996, article "Methods in Enzymology"
   MILLERCALOS, GENE TRANSFER VECTORS FOR MAMMALIAN CELLS, 1987
   AUSUBEL, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1987
   MULLIS, PCR: THE POLYMERASE CHAIN REACTION, 1994
   ZENG ET AL., INT J RADIAT ONCOL BIOL PHYS., vol. 86, 2013, pages 343 - 9
   CONLON ET AL., J. CLIN. ONCOL., vol. 33, 2015, pages 74 - 82
   KOBAYASHI T ET AL., EMBO J, vol. 13, 1994, pages 5818 - 25
   HARA I ET AL., J EXP MED, vol. 182, 1995, pages 1609 - 14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.